Trends & Analysis

#Funding #Investment

New biopharma deals report reveals spending trends 

Clarivate has released its annual Biopharma Deals Report, which highlights emerging market trends and features detailed analysis of the key deals of 2021 and potential implications for 2022, the full extent of which can be found on clarivate.com.  This year’s report finds US biotech companies raised the… Read More

#News #Trends & Analysis

#Antimicrobials #Bioconvergence #Drug development #Immunology / Virology & Vaccines #mRNA

Bioconvergence: Future trends for biomedicine

Dr. Tom Knapman, Director of Strategic Brand at SCIEX, explains how bioconvergent advances will help to drive key health trends in the coming year. As we move into 2022, we will see more and more advances in bioconvergence – biological, physical, and computing technologies inspired by nature. We expect these… Read More

#Exclusive Content #News #Opinion #Trending News #Trends & Analysis

#Lab automation #Lab of the future #Liquid handling

Lab of the future: an expert view

The Lab of the Future will fuse automation, speed and remote work says Thomas Marshall, Senior Staff Research Scientist at Beckman Coulter Life Sciences. Labs across research areas—life sciences, pharma, and biotech—were already becoming remarkably automated but the pandemic has spurred a new kind of urgency in automating both individual… Read More

#Exclusive Content #News #Trends & Analysis

#Biomedical research #Data #Research

Spotlight: Tackling the issue of scientific data waste 

More than half of all scientific research is irreproducible, and more than 80% of scientific research data is being lost within 20 years. In the biomedical field alone, irreproducible research costs the industry £28 billion (US$38 billion) every year. Megan Thomas talks to Founder of Labstep Jake Schofield, about… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone #Trends & Analysis

#ATMP #Biopharmaceuticals #Regulatory

Five marketing strategies for ATMPs 

The advanced therapy medicinal products (ATMPs) sector holds great promise. However, multidisciplinary strategies that begin early in the development process should be adopted, says Christian Schneider, head of Biopharma Excellence and Chief Medical Officer at PharmaLex. He outlines five strategies for avoiding pitfalls and boosting the success rates of… Read More

#Editor's Choice #Intelligence #News #Opinion #Regulatory #Trends & Analysis

#Biopharmaceuticals #Drug development #Drug innovation #Funding

Key take-aways from new R&D trends report 

As the global Covid-19 pandemic enters its third year, the life sciences innovation system is setting new records in the level of investment, activity, and scientific progress, according to the IQVIA Institute. In its report, Global Trends in R&D: Overview through 2021, the IQVIA assesses the trends… Read More

#News #Trends & Analysis

#Life sciences #Market reporting #Pharmaceutical research #Public health

How strong is the digital talent in the global pharma sector? 

DDW’s Megan Thomas looks at three regions and their approach to digitalisation. 1. United Kingdom  A report published by the Association of the British Pharmaceutical Industry (ABPI) has identified the skills and training conditions needed for the future success of UK life sciences. George… Read More

#News #Trends & Analysis

#Clinical trials #Comment #Pharmaceuticals

Do end-to-end CDMOs hold the secret to success in cell and gene therapy?

The cell and gene therapy (CGT) industry is booming, say Sergio Lainez Vicente (Senior Manager of Business Operations in the Cell & Gene Therapy / Large Molecule area) and Jaleel Shujath (Vice President of Marketing and Content), at Absorption Systems, a Pharmaron company. Around 1200 potential cell and gene… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Biopharma #Market reporting #Moderna #Pfizer #Pharma

What drove the top bio/pharma companies’ growth in 2021? 

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported… Read More

#News #Trending News #Trends & Analysis

#Biotechnology #DNA #Drug discovery #mRNA #Synthetic chemistry

From synthetic biology to synthesising DNA: helping advance research 

Evonetix is reimagining biology. Dr Vijay Narayan, Head of Physics, Dr Stuart Crosby, Head of Synthetic Chemistry, and Daniel Bygrave, Principal Software Engineer, offer insight into the technology being developed by the company and its relevance for researchers.  “I have always been intrigued by interdisciplinary environments,’… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Biotechnology #Clinical trials #Comment #Data science #Decentralised clinical trials #Digital

Predictions and perspectives on the future of DCTs 

“The message was clear from industry leaders this year whether on social media or conferences: today’s clinical trials need decentralised solutions”, says Temitope Keyes, Executive Director Business Development at encapsia, commenting on the decentralised clinical trial (DCT) event horizon.  Clinical trials are now more complex… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Antigen #Biotechnology #Immunology / Virology & Vaccines #mRNA #RNA #Therapeutics

What’s next for RNA-based medicine post-Covid-19?

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what’s next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in… Read More

#Covid-19 #Exclusive Content #News #Trends & Analysis

#CRO #Drug development #Drug discovery #Genomics

CROs: Drug discovery expertise on hand  

Listen to this article on the DDW Podcast: Lu Rahman asks Laura Hinton, Operations Director at Gentronix, to offer some insight into the contract research organisation (CRO) market and how Gentronix is making its presence known in this sector.  Gentronix is a specialist contract research organisation (CRO) based in the UK, focused on delivering… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Analysis #Biotechnology #Health #Life sciences

Four pillars of the Lithuanian life sciences growth strategy 

Click here to watch this as a video Lithuania is dedicating time and resources establishing itself as a life sciences and biotechnology hub of excellence. DDW’s Megan Thomas analyses four pillars of Lithuania’s growth strategy, which involves ensuring female scientists take leading roles in industry, focusing on investment, developing a… Read More

#Editor's Choice #Exclusive Content #News #Trends & Analysis

#Cancer #Cancer research #Comment #Healthcare #Public health

Close the care gap: World Cancer Day 2022 

2022’s World Cancer Day theme is “Close the Care Gap”1 and is focused on raising awareness of the cancer care equity gap that affects almost everyone, in high as well as low- and middle-income countries, and costs lives. DDW’s Megan Thomas comments on the crisis as well as initiatives that are working… Read More

#Cancer Research #Editor's Choice #Intelligence #News #Opinion #Trends & Analysis